Neoadjuvant Ipilimumab in Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Prostate Cancer
Interventions
DRUG

Leuprolide Acetate

22.5 mg administered as a single intramuscular 3 month depot.

DRUG

Ipilimumab

10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy.

PROCEDURE

Radical Prostatectomy

Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER